Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies PharmaTimesParsortix platform to support minimally invasive analysis across various cancer trialsOncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) PharmaTimes Parsortix platform to support minimally invasive analysis across various cancer trials Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves Enhertu for two HER2-positive early breast cancer indicationsNext: Another LAG-3 setback as Regeneron drug fails phase 3 trial Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
